Back to top

Image: Bigstock

Sucampo Pharmaceuticals, Inc.

Read MoreHide Full Article

Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Amitiza's solid prescription growth so far this year demonstrates persistently robust demand. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. However, Sucampo’s dependence on Amitiza for growth is concerning. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. Shares of the company have underperformed the Medical-Drugs industry in the past one year.